TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?

Slides:



Advertisements
Similar presentations
Il controllo circadiano della pressione intraoculare: implicazioni farmacologiche N. ORZALESI, P. FOGAGNOLO Università degli Studi di Milano Ospedale San.
Advertisements

The target IOP is the mean IOP obtained with treatment that prevents further glaucomatous damage in the eye of the individual under consideration. The.
Paras Guide to Glaucoma
Biomechanical Properties of the Cornea in Normal- Tension Glaucoma Authors: Leonidas Traipe Ines Cayuqueo Fabiola Cerfogli Claudia Goya Allister Gibbons.
CATARACT SUEGRY AND DIABETES Indications of surgery: 1) Visual loss 2)Surveillance of retinopathy 3)Laser therapy.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
Collaboration in the care of glaucoma patients and glaucoma suspects
0 Glaucoma can take your sight away. Keep Vision in Your Future.
In the name of god Target IOP S.M.Shahshahan M.D Feb 2010.
4/19/2017 Managing Patients With Ocular Hypertension Results From The Ocular Hypertension Treatment Study (OHTS) The American Glaucoma Society Michael.
The Canadian Association of Optometrists
OPEN ANGLE GLAUCOMA Frank J. Weinstock, MD, FACS Professor of Ophthalmology- NEOUCOM Canton, Ohio USA.
The Ocular Hypertension Treatment Study (OHTS) Supported by the National Eye Institute, National Center on Minority Health and Health Disparities, Research.
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
 GLAUCOMA.  BY GROUPS 3 1. Siti Hadijah ( ) 2. I Putu Adi Styawan ( ) 3. Jaka Primadhana. R ( ) 4. Komang Ayu Pradnya Antari ( )
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Will my Glaucoma patient lose vision ?
Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema Sponsored by the National Eye Institute,
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I
Universita’ di Catania, Italia Clinica Oculistica Dir.: Prof. A. Reibaldi Purpose: To evaluate the efficacy and safety of Pneumotrabeculoplasty (PNT) in.
Does Greater Long-Term IOP Variability Increase Probability of Primary Open Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)? M.O. Gordon,
Glaucoma and Penetrating Keratoplasty : Incidence, Risk Factors, and Outcomes Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author.
Cataract Surgery After Trabeculectomy: The Effect on Trabeculectomy Function Husain R, Liang S, Foster PJ. Cataract surgery after trabeculectomy: the effect.
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Glaucoma Case Studies James C. Tsai, M.D. Associate Professor of Ophthalmology Director, Glaucoma Division Edward S. Harkness Eye Institute Columbia University.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
Combined cataract surgery and endoscopic cyclophotocoagulation in patients with glaucoma without prior incisional glaucoma surgery Matthew P. Traynor,
PHACO-TRAB VERSUS PHACO ONLY IN EYES WITH ADVANCED OR END-STAGE GLAUCOMA WITH CONTROLLED INTRAOCULAR PRESSURE AND VISUALLY SIGNIFICANT CATARACT Liaska.
Dr. Abdullah Al-Amri Ophthalmology Consultant
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Sponsored by the National Eye Institute,
GLAUCOMA داء الزرقاء.
Comparison of efficacy and safety of Travoprost and Bimatoprost plus Timolol fixed combinations in open angle glaucoma patients previously treated with.
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
Efficacy and Safety of the Ex-PRESS Glaucoma Mini-Shunt with Intraoperative 5-Fluorouracil ASCRS 2009 – San Francisco A. Balashanmugam, MD, L. Farrokh-Siar,
The Ocular Hypertension Treatment Study Group (OHTS)
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.
PRIMARY OPEN ANGLE GLAUCOMA PROF.DR.ÖZCAN OCAKOĞLU.
Glaucoma studies, IOP and treatment rationale W. H. Morgan RPH, LEI and PMH.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Glaucoma Lily T. Im, MD. What is glaucoma?   Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness.
D.r Nishant Nawani, MS Dr. Surinder Singh Pandav, MD Dr. Amit Gupta, MD Dr. Sushmita Kaushik, MD Advanced Eye Centre PGIMER, Chandigarh The authors have.
Understanding Glauco ma. Femi Babalola Rachel eye center Garki, Abuja.
María Alejandra Carrasco, MD Mendoza. Argentina
IMPACT OF CATARACT SURGERY UPON INTRAOCULAR PRESURE CONTROL IN GLAUCOMA PATIENTS Crenguta Feraru, Anca Pantalon “Gr.T. Popa” University of Medicine and.
PROTECTING CELLS IN THE EYE AT RISK OF DAMGE FROM GLAUCOMA
Tulsi Changulani 1,*, Jenny Bo 2, Mei-Ling Cheng 1, Andrew Tatham 1
LONG-TERM RESULTS OF DEEP SCLERECTOMY IN NORMAL-TENSION GLAUCOMA
Selective laser trabeculoplasty in Korean eyes with medically uncontrolled pseudoexfoliation glaucoma Su Chan Lee1, Jung Hyun Lee1,
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Safety of medication reduction for Primary Angle Closure (PAC) –
COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP
Factors Influencing Patient Satisfaction in a Glaucoma Population
Review of Glaucoma Suspect
Neuroretinal Rim Recovery In Narrow Angle Glaucoma After Intraocular Pressure Lowering With Topical Medications  – Case Report Božić M.1,2, Marković V.
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
Lasers in Glaucoma: Meta analysis
Risk stratification and calculators
Glaucoma.
A presentation to: Meeting name Date
Diagnostic Considerations in Contemporary Glaucoma Management COPE GL
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Winthrop University Hospital
Presentation transcript:

TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?

``Doctor is my glaucoma likely to get worse?``

``Doctor will my eye condition get worse?``  What is the diagnosis (OHT vs NTG vs POAG early or late ?)  Does the patient have the published risk Factor for progression?

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

Ocular hypertension treatment study  Aim  To determine if glaucoma drops delays or prevents glaucoma in ocular hypertensives Arch Ophthalmol 120: , 2002.

OHTS - methods  RCT of 1600 patients  IOP 24-32mmHg in one eye and in other eye  Normal discs and fields  Drops prescribed to achieve IOP of ≤24mmHg AND at least 20% drop from baseline

Results  At 5 years  4.4% of treated group had progressed to POAG  9.5% of untreated

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

What are the risk factors for progression with OHT? OHTS study

OHTS conclusions  Factors associated with progression  ``I treat if:``  Older age  High CDR (vertical or horizontal) > 0.4  High PSD  IOP  Thinner cornea

CCT and Glaucoma Risk

What are the risk factors for progression in NTG? NTGS study

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

Normal tension glaucoma study  Aim  To determine if IOP plays a part in NTG

NTGS - methods  239 patients recruited  Uni or bilateral NTG as defined by  IOP <21 in 10 baseline measurements AND  Glaucomatous cupping  Defined type and severity of field loss

NTGS - methods  Randomised immediately if  VF defect threatening fixation  Previously documented disease progression  Others randomised when evidence of progression

NTGS  145 (of 239) patients randomised  One eye randomised to  Treatment  Drops, ALT or surgery to achieve 30% reduction in IOP  No treatment until evidence of progression  Other eye could be treated in this group

NTGS results  30% drop achieved in half without surgery  Once 30% drop achieved rate of progressive field loss was lower than group that did not receive treatment (after allowing for cataract effect which was higher in treated group)

NTGS results  Rate of progression in untreated NTG highly variable  Half did not progress on VF in 5 years  Factors associated with progression  Female  Migraine  Disc haemorrhages on presentation

NTGS conclusions  Overall, lowering IOP in NTG slows progression.  However, over half of patients did not progress without treatment at 5 years.

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) 6020 Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

What are the risk factors for progression in NTG? NTGS study

Factors associated with progression ``I am aggressive if:`` – Female – Migraine – Disc haemorrhages on presentation

What are the risk factors for progression in early glaucoma? EMGS study

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

Early Manifest Glaucoma Trial Compared immediate treatment versus no (or delayed) treatment for patients with newly diagnosed POAG Diagnosis based on reproducible visual field defects Included NTG

EMGT 255 patients Randomised to ▫ ALT and betaxolol ▫ No treatment If IOP >25mmHg in treated (>35 untreated) → Latanoprost added If remains high → individualised treatment

EMGT  End point  Progression of field and/or disc

EMGT - results  Over 6 years  62% untreated versus 45% of treated group progressed  Median time to progression 66 months treated versus 48 months untreated

Risk of Progression DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) 6245 Advanced POAG (AGIS-7 yrs)

What are the risk factors for progression in early glaucoma? EMGS study

Early POAG risk factors (EMGS)  Baseline factors  Pseudoexfoliation  Older age  Higher IOP  Worse mean deviation  Follow up factors  IOP  Each 1mmHg reduction from baseline reduced risk of progression by 10%  Disc haemorrhages

Early POAG risk factors (EMGS) Factors associated with progression ``I am aggressive if:``  Pseudo exfoliation  Bilateral disease  Older age  Higher IOP  Worse mean deviation  Disc hemorrhage

Risk of Progression-Advanced glaucoma DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs)

Advanced Glaucoma Intervention Study  Aim  To assess the outcome of sequences of laser and surgical interventions in eyes that have failed on medical treatment

AGIS POAG, uncontrolled with drops Randomised to 2 groups 1. Trab → ALT → Trab 2. ALT → Trab → ALT Medical treatment as required 789 patients followed up for at least 5 years

AGIS outcomes  Primary outcome  Decreased vision (substantial VA or VF decrease)

AGIS results  Vision better in blacks if had ALT first  In whites  Vision better in laser group for first 4 years  Then better in surgery group

AGIS results  Side arm looked at IOP and VF loss  Divided into 2 groups  IOP <18mmHg at 100% visits (mean = 12.3mmHg) = little VF deterioration  IOP <18mmHg at <50% of study visits (mean = 20.2mmHg) = significantly more VF deterioration

100% of visits < 18mmHg 50-75% of visits < 18mmHg 0% of visits < 18mmHg % of visits < 18mmHg

AGIS conclusions (1992)  Blacks should have laser first  Whites should have trab first

AGIS conclusions  Relationship between low IOP and VF loss remains important finding  In advanced glaucoma, lowering IOP to low teens means most will not progress

Risk of Progression-Advanced glaucoma DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) Early POAG (EMGS study 6 yrs ) Advanced POAG (AGIS-7 yrs) Not Known 30 VA 14 VF (IOP <15mmhg)

 Factors associated with progression  ``I am aggressive if:``  Older age  Lower education  Good VA  DM  High IOP > 18  IOP fluctuation AGIS conclusions

Collaborative Initial Glaucoma Treatment Study (CIGTS)  Does not provide direct evidence that IOP has an impact on glaucomatous progression, but you need to know about it… AIM: to assess the effect on early-diagnosed OAG of initial Tx with either topical meds or trab

CIGTS - Methods  Prospective RCT  OAG (POAG, Pigmentary, PEX)  N=607  Randomized → Medical management ↘ Trabeculectomy  IOP target customized for each patient  Primary End Point: progression of VF loss

CIGTS – Results at 5yrs Medical TreatmentSurgical Treatment IOP reduction 28mmHg → 17-18mmHg27mmHg → 14-15mmHg Progression at 5 years No progression Surgical group is at increased risk of visual loss initially but by 4yrs both groups are comparable

CIGTS summary  Surgery resulted in  Lower IOP  More cataract  More ocular side effects  Initial ↓ vision  Initial ↓ visual field

CIGTS conclusions  Results do not support altering current practice of medical treatment first

``Doctor is my glaucoma likely to get worse?``

DiagnosisRisk of progression with no Rx (%) Risk of progression with Rx (%) OHT OHT study 5 yrs NTG (CNTG study 6 yrs ) 6020 Early POAG (EMGS study 6 yrs ) 6245 Advanced POAG (AGIS-7 yrs) Not Known30 VA 14 VF (IOP <15mmhg) RISK OF PROGRESSION THE BEST EVIDENCE SUMMARY

Risk Factors for ProgressionFactors OH  Glaucoma Glaucoma  Progression Higher age OHTS AGIS, CIGTS, EMGT CCTOHTS C:D ratio OHTS Diabetes mellitus OHTS AGIS, CIGTS Disc hemorrhage EMGT, NTGS IOP (higher) OHTSEMGT IOP (over f/u) OHTSEMGT MaleOHTSAGIS PXFEMGT Race (non-white) OHTSCIGTS Visual field OHTSEMGT

Glaucoma Risk Calculation Results Patient Age Corneal Thickness microns IOP PSD Vertical Cup / Disk Ratio Risk of developing glaucoma within the next five years. Risk without treatment % Risk with treatment %

Patient Age Corneal Thickness microns IOP PSD Vertical Cup / Disk Ratio Glaucoma Risk Calculation Results Risk of developing glaucoma within the next five years. Risk without treatment % Risk with treatment %

My “take home messages” 1. Every mmHg helps (EMGT) 2. If get IOP very low (12mmHg) most patients will not progress (AGIS) 3. NTG is a funny disease - Many do not progress - If do – only proven treatment is reducing IOP 4. Not all OHT needs treated – assess risk on individual basis and discuss with patient